- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit | 1 | GlobeNewswire (USA) | ||
| Di | Calidi Biotherapeutics appoints Corsee Sanders to board | 1 | Investing.com | ||
| Di | Calidi Biotherapeutics beruft Corsee Sanders in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 18.06. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study | 89 | GlobeNewswire (Europe) | SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 05.06. | RedChip Companies, Inc.: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 | 472 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / June 5, 2026 / RedChip Companies will host an investor webinar with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) ("Calidi" or "the Company") on June 9, 2026, at... ► Artikel lesen | |
| 29.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Required NYSE American Disclosure | 211 | GlobeNewswire (Europe) | SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines... ► Artikel lesen | |
| 14.05. | Calidi BioTherapeutics GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
| 14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | 269 | GlobeNewswire (Europe) | Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end... ► Artikel lesen | |
| 08.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com | ||
| 20.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Calidi to present RedTail platform data at Iceland conference | 2 | Investing.com | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Calidi BioTherapeutics GAAP EPS of -$5.95 | 2 | Seeking Alpha | ||
| 27.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | 195 | GlobeNewswire (Europe) | Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| CLINUVEL | 5,904 | -1,73 % | Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,931 | +1,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,067 | -3,18 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| CYTODYN | 0,210 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,255 | -2,81 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,250 | -0,94 % | Optionshandel bei Denali Therapeutics zieht stark an | ||
| CEL-SCI | 0,760 | -9,52 % | CEL SCI CORP - 8-K, Current Report | ||
| CYTOKINETICS | 72,00 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,314 | +0,08 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,919 | -1,82 % | CytomX Therapeutics, Inc. - 8-K, Current Report | ||
| FAETH THERAPEUTICS | 23,500 | +2,75 % | Baird initiates Faeth Therapeutics stock with outperform rating | ||
| FATE THERAPEUTICS | 1,600 | -13,04 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,162 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.